CoronaVac COVID-19 Vaccine-Induced Anaphylaxis: Clinical Characteristics and Revaccination Outcomes

Abstract

Wannada Laisuan,1 Chamard Wongsa,2 Chirawat Chiewchalermsri,3 Torpong Thongngarm,2 Ticha Rerkpattanapipat,1 Pansa Iamrahong,4 Chulapha Ruangwattanachok,4 Sira Nanthapisal,5 Mongkhon Sompornrattanaphan2 1Division of Allergy, Immunology and Rheumatology, Department of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 2Division of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand; 3Department of Medicine, Panyananthaphikkhu Chonprathan Medical Center, Srinakharinwirot University, Nonthaburi, Thailand; 4Clinical Pharmacy Section, Pharmacy Division, Faculty of Medicine, Ramathibodi Hospital, Mahidol University, Bangkok, Thailand; 5Department of Pediatrics, Faculty of Medicine, Thammasat University, Pathum Thani, ThailandCorrespondence: Mongkhon SompornrattanaphanDivision of Allergy and Clinical Immunology, Department of Medicine, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandTel [phone]Fax [phone]Email [email protected]: Anaphylaxis to CoronaVac, an inactivated vaccine against COVID-19, is extremely rare. We report 12 cases of anaphylaxis after CoronaVac administration, focusing on clinical characteristics and management outcomes. Skin test and graded vaccine challenge were successfully performed in our cases and might be considered if an inactivated vaccine is the only remaining option.Keywords: anaphylaxis, COVID-19 vaccine, drug allergy, excipient, vaccine allergy, COVID-19, skin testing

Keywords

• anaphylaxis
• covid-19 vaccine
• drug allergy
• excipient
• vaccine allergy
• covid-19
• skin testing